[{"id":"f2db16c9-71f0-4157-a48e-228ddfc05996","acronym":"DECIST","url":"https://clinicaltrials.gov/study/NCT04157127","created_at":"2021-01-29T07:19:57.046Z","updated_at":"2024-07-02T16:35:28.793Z","phase":"Phase 1","brief_title":"Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04157127 - DECIST","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dubodencel (DOC1021)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 08/03/2020","start_date":" 08/03/2020","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2023-11-18"}]